Skyhawk Therapeutics Announces Final Fifteen-Month Results from Phase 1/2 Clinical Trial of SKY-0515 in Huntington’s Disease Patients 

Encouraging progress is emerging from Huntington’s disease research. Skyhawk Therapeutics has reported final results from its Phase 1/2 trial of SKY‑0515, a once‑daily oral treatment designed to reduce levels of the toxic huntingtin protein as well as PMS1, another protein associated with disease onset.

Participants receiving SKY‑0515 showed meaningful improvement on the cUHDRS, a composite measure used to track Huntington’s disease progression, when compared with a matched natural‑history control group. Importantly, the benefit appeared across all four components of the scale — daily functioning, movement, processing speed, and reading speed — a consistency that has researchers feeling optimistic.

Although the study was small and lacked a simultaneous placebo group, seeing steady, cross‑measure improvement at this early stage is exactly the kind of signal researchers look for before advancing to larger trials.

 BOSTON, Mass., September 15 2026 – Skyhawk Therapeutics, Inc., a clinical-stage biotechnology company developing novel small molecule therapies designed to modulate RNA targets, ttoday announced final fifteen-month results from its Phase 1/2 clinical trial evaluating SKY-0515, an investigational oral treatment for Huntington’s disease (HD).

The Phase 1/2 patient study is a randomized, double-blind, placebo-controlled parallel-group study evaluating two dose levels of SKY-0515 in patients over twelve weeks, followed by a twelve-month blinded Extension period during which all participants receive active treatment at either a low or high dose (4mg or 9mg), with the majority of patients on the 9 mg dose.

‍At Month 15, the primary timepoint, patients treated with SKY-0515 improved on the cUHDRS by an average of 0.94 points from where they started, while a comparison group of untreated patients from the Enroll-HD natural history database declined by an average of 0.65 points. The gap between the two groups was 1.59 points (95% CI: 1.09, 2.09; p<0.001).

‍SKY-0515 patients also did better than the comparison group on each of the four measures that make up the cUHDRS: daily function (Total Functional Capacity, +0.98 points), movement (Total Motor Score, −9.38 points, where a lower score is better), processing speed (Symbol Digit Modalities Test, +4.15 points) and reading speed (Stroop Word Reading Test, +4.18 points). All differences were statistically significant.

Additional information regarding FALCON-HD, including participating sites and eligibility criteria, is available at ClinicalTrials.gov and www.FALCON-HD.com.

Share this article

Similar Posts

View all news